Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy

Andrés J M Ferreri, Maurilio Ponzoni, Massimo Guidoboni, Carlo De Conciliis, Antonio Giordano Resti, Benedetta Mazzi, Antonia Anna Lettini, J. Demeter, Stefania Dell'Oro, Claudio Doglioni, Eugenio Villa, Mauro Boiocchi, Riccardo Dolcetti

Research output: Article

171 Citations (Scopus)

Abstract

Purpose: Some infectious agents contributing to lymphomagenesis have been considered targets for new therapeutic strategies. Chlamydia psittaci DNA has been detected in 80% of ocular adnexal lymphomas. The present pilot study was carried out to assess whether C psittaci-eradicating antibiotic therapy is associated with tumor regression in ocular adnexal lymphomas. Patients and Methods: Nine patients with C psittaci-positive marginal-zone B-cell lymphoma of the ocular adnexa at diagnosis or relapse were treated with doxycycline 100 mg, bid orally, for 3 weeks. The presence of C psittaci DNA in peripheral-blood mononuclear cells (PBMCs) was also assessed before and after treatment in seven patients. Objective lymphoma regression was assessed 1, 3, and 6 months after therapy conclusion and every 6 months during follow-up. Results: All patients completed antibiotic therapy with excellent tolerability. At 1 month from doxycycline assumption, chlamydial DNA was no longer detectable in PBMCs of all four positive patients. Objective response was complete in two patients, partial response (> 50%) was observed in two patients, and minimal response (<50%) was observed in three patients. Duration of response in the seven responders was 12+, 29+, 31+, 8+, 7+, 2+, and 1+ months, respectively. Conclusion: C psittaci-eradicating antibiotic therapy with doxycycline is followed by objective response in patients with ocular adnexal lymphoma, even after multiple relapses of the disease. A confirmatory, large, phase II trial is warranted to confirm whether this fast, cheap, and well-tolerated therapy could replace other more aggressive strategies as first-line treatment against ocular adnexal lymphomas.

Original languageEnglish
Pages (from-to)5067-5073
Number of pages7
JournalJournal of Clinical Oncology
Volume23
Issue number22
DOIs
Publication statusPublished - 2005

Fingerprint

Chlamydophila psittaci
Lymphoma
Anti-Bacterial Agents
Doxycycline
Therapeutics
DNA
Blood Cells
Recurrence
Marginal Zone B-Cell Lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ferreri, A. J. M., Ponzoni, M., Guidoboni, M., De Conciliis, C., Resti, A. G., Mazzi, B., ... Dolcetti, R. (2005). Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. Journal of Clinical Oncology, 23(22), 5067-5073. https://doi.org/10.1200/JCO.2005.07.083

Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. / Ferreri, Andrés J M; Ponzoni, Maurilio; Guidoboni, Massimo; De Conciliis, Carlo; Resti, Antonio Giordano; Mazzi, Benedetta; Lettini, Antonia Anna; Demeter, J.; Dell'Oro, Stefania; Doglioni, Claudio; Villa, Eugenio; Boiocchi, Mauro; Dolcetti, Riccardo.

In: Journal of Clinical Oncology, Vol. 23, No. 22, 2005, p. 5067-5073.

Research output: Article

Ferreri, AJM, Ponzoni, M, Guidoboni, M, De Conciliis, C, Resti, AG, Mazzi, B, Lettini, AA, Demeter, J, Dell'Oro, S, Doglioni, C, Villa, E, Boiocchi, M & Dolcetti, R 2005, 'Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy', Journal of Clinical Oncology, vol. 23, no. 22, pp. 5067-5073. https://doi.org/10.1200/JCO.2005.07.083
Ferreri, Andrés J M ; Ponzoni, Maurilio ; Guidoboni, Massimo ; De Conciliis, Carlo ; Resti, Antonio Giordano ; Mazzi, Benedetta ; Lettini, Antonia Anna ; Demeter, J. ; Dell'Oro, Stefania ; Doglioni, Claudio ; Villa, Eugenio ; Boiocchi, Mauro ; Dolcetti, Riccardo. / Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 22. pp. 5067-5073.
@article{c111dc6ebe884a3f9c513127a66beb9f,
title = "Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy",
abstract = "Purpose: Some infectious agents contributing to lymphomagenesis have been considered targets for new therapeutic strategies. Chlamydia psittaci DNA has been detected in 80{\%} of ocular adnexal lymphomas. The present pilot study was carried out to assess whether C psittaci-eradicating antibiotic therapy is associated with tumor regression in ocular adnexal lymphomas. Patients and Methods: Nine patients with C psittaci-positive marginal-zone B-cell lymphoma of the ocular adnexa at diagnosis or relapse were treated with doxycycline 100 mg, bid orally, for 3 weeks. The presence of C psittaci DNA in peripheral-blood mononuclear cells (PBMCs) was also assessed before and after treatment in seven patients. Objective lymphoma regression was assessed 1, 3, and 6 months after therapy conclusion and every 6 months during follow-up. Results: All patients completed antibiotic therapy with excellent tolerability. At 1 month from doxycycline assumption, chlamydial DNA was no longer detectable in PBMCs of all four positive patients. Objective response was complete in two patients, partial response (> 50{\%}) was observed in two patients, and minimal response (<50{\%}) was observed in three patients. Duration of response in the seven responders was 12+, 29+, 31+, 8+, 7+, 2+, and 1+ months, respectively. Conclusion: C psittaci-eradicating antibiotic therapy with doxycycline is followed by objective response in patients with ocular adnexal lymphoma, even after multiple relapses of the disease. A confirmatory, large, phase II trial is warranted to confirm whether this fast, cheap, and well-tolerated therapy could replace other more aggressive strategies as first-line treatment against ocular adnexal lymphomas.",
author = "Ferreri, {Andr{\'e}s J M} and Maurilio Ponzoni and Massimo Guidoboni and {De Conciliis}, Carlo and Resti, {Antonio Giordano} and Benedetta Mazzi and Lettini, {Antonia Anna} and J. Demeter and Stefania Dell'Oro and Claudio Doglioni and Eugenio Villa and Mauro Boiocchi and Riccardo Dolcetti",
year = "2005",
doi = "10.1200/JCO.2005.07.083",
language = "English",
volume = "23",
pages = "5067--5073",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "22",

}

TY - JOUR

T1 - Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy

AU - Ferreri, Andrés J M

AU - Ponzoni, Maurilio

AU - Guidoboni, Massimo

AU - De Conciliis, Carlo

AU - Resti, Antonio Giordano

AU - Mazzi, Benedetta

AU - Lettini, Antonia Anna

AU - Demeter, J.

AU - Dell'Oro, Stefania

AU - Doglioni, Claudio

AU - Villa, Eugenio

AU - Boiocchi, Mauro

AU - Dolcetti, Riccardo

PY - 2005

Y1 - 2005

N2 - Purpose: Some infectious agents contributing to lymphomagenesis have been considered targets for new therapeutic strategies. Chlamydia psittaci DNA has been detected in 80% of ocular adnexal lymphomas. The present pilot study was carried out to assess whether C psittaci-eradicating antibiotic therapy is associated with tumor regression in ocular adnexal lymphomas. Patients and Methods: Nine patients with C psittaci-positive marginal-zone B-cell lymphoma of the ocular adnexa at diagnosis or relapse were treated with doxycycline 100 mg, bid orally, for 3 weeks. The presence of C psittaci DNA in peripheral-blood mononuclear cells (PBMCs) was also assessed before and after treatment in seven patients. Objective lymphoma regression was assessed 1, 3, and 6 months after therapy conclusion and every 6 months during follow-up. Results: All patients completed antibiotic therapy with excellent tolerability. At 1 month from doxycycline assumption, chlamydial DNA was no longer detectable in PBMCs of all four positive patients. Objective response was complete in two patients, partial response (> 50%) was observed in two patients, and minimal response (<50%) was observed in three patients. Duration of response in the seven responders was 12+, 29+, 31+, 8+, 7+, 2+, and 1+ months, respectively. Conclusion: C psittaci-eradicating antibiotic therapy with doxycycline is followed by objective response in patients with ocular adnexal lymphoma, even after multiple relapses of the disease. A confirmatory, large, phase II trial is warranted to confirm whether this fast, cheap, and well-tolerated therapy could replace other more aggressive strategies as first-line treatment against ocular adnexal lymphomas.

AB - Purpose: Some infectious agents contributing to lymphomagenesis have been considered targets for new therapeutic strategies. Chlamydia psittaci DNA has been detected in 80% of ocular adnexal lymphomas. The present pilot study was carried out to assess whether C psittaci-eradicating antibiotic therapy is associated with tumor regression in ocular adnexal lymphomas. Patients and Methods: Nine patients with C psittaci-positive marginal-zone B-cell lymphoma of the ocular adnexa at diagnosis or relapse were treated with doxycycline 100 mg, bid orally, for 3 weeks. The presence of C psittaci DNA in peripheral-blood mononuclear cells (PBMCs) was also assessed before and after treatment in seven patients. Objective lymphoma regression was assessed 1, 3, and 6 months after therapy conclusion and every 6 months during follow-up. Results: All patients completed antibiotic therapy with excellent tolerability. At 1 month from doxycycline assumption, chlamydial DNA was no longer detectable in PBMCs of all four positive patients. Objective response was complete in two patients, partial response (> 50%) was observed in two patients, and minimal response (<50%) was observed in three patients. Duration of response in the seven responders was 12+, 29+, 31+, 8+, 7+, 2+, and 1+ months, respectively. Conclusion: C psittaci-eradicating antibiotic therapy with doxycycline is followed by objective response in patients with ocular adnexal lymphoma, even after multiple relapses of the disease. A confirmatory, large, phase II trial is warranted to confirm whether this fast, cheap, and well-tolerated therapy could replace other more aggressive strategies as first-line treatment against ocular adnexal lymphomas.

UR - http://www.scopus.com/inward/record.url?scp=24644519021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644519021&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.07.083

DO - 10.1200/JCO.2005.07.083

M3 - Article

VL - 23

SP - 5067

EP - 5073

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 22

ER -